JP2019536439A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019536439A5 JP2019536439A5 JP2019518301A JP2019518301A JP2019536439A5 JP 2019536439 A5 JP2019536439 A5 JP 2019536439A5 JP 2019518301 A JP2019518301 A JP 2019518301A JP 2019518301 A JP2019518301 A JP 2019518301A JP 2019536439 A5 JP2019536439 A5 JP 2019536439A5
- Authority
- JP
- Japan
- Prior art keywords
- fusion protein
- seq
- amino acid
- type
- domain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108020001507 fusion proteins Proteins 0.000 claims description 581
- 102000037865 fusion proteins Human genes 0.000 claims description 560
- 235000001014 amino acid Nutrition 0.000 claims description 213
- 150000001413 amino acids Chemical class 0.000 claims description 147
- 238000006467 substitution reaction Methods 0.000 claims description 142
- 230000004048 modification Effects 0.000 claims description 40
- 238000012986 modification Methods 0.000 claims description 40
- 125000000539 amino acid group Chemical group 0.000 claims description 28
- 235000018417 cysteine Nutrition 0.000 claims description 26
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 26
- 239000004475 Arginine Substances 0.000 claims description 22
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 22
- 229920001184 polypeptide Polymers 0.000 claims description 22
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 22
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 22
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 20
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 20
- 235000003704 aspartic acid Nutrition 0.000 claims description 20
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 20
- 235000013922 glutamic acid Nutrition 0.000 claims description 20
- 239000004220 glutamic acid Substances 0.000 claims description 20
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 14
- 239000004472 Lysine Substances 0.000 claims description 14
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims description 14
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 14
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 13
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 13
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 13
- 235000004279 alanine Nutrition 0.000 claims description 13
- 239000004474 valine Substances 0.000 claims description 13
- 230000007935 neutral effect Effects 0.000 claims description 9
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 claims description 7
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 claims description 7
- 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 claims description 7
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 7
- 108091006020 Fc-tagged proteins Proteins 0.000 claims description 4
- 102100025423 Bone morphogenetic protein receptor type-1A Human genes 0.000 claims description 3
- 101000934638 Homo sapiens Bone morphogenetic protein receptor type-1A Proteins 0.000 claims description 3
- 101100437153 Rattus norvegicus Acvr2b gene Proteins 0.000 claims description 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 3
- GPTFURBXHJWNHR-UHFFFAOYSA-N protopine Chemical compound C1=C2C(=O)CC3=CC=C4OCOC4=C3CN(C)CCC2=CC2=C1OCO2 GPTFURBXHJWNHR-UHFFFAOYSA-N 0.000 claims description 3
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 161
- 108020003175 receptors Proteins 0.000 description 36
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 33
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 33
- 238000000034 method Methods 0.000 description 22
- 210000004027 cell Anatomy 0.000 description 18
- 102000040430 polynucleotide Human genes 0.000 description 18
- 108091033319 polynucleotide Proteins 0.000 description 18
- 239000002157 polynucleotide Substances 0.000 description 18
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 16
- 108010059616 Activins Proteins 0.000 description 14
- 102100026818 Inhibin beta E chain Human genes 0.000 description 14
- 239000000488 activin Substances 0.000 description 14
- 230000002378 acidificating effect Effects 0.000 description 12
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical group OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 8
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical group OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 8
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical group NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 8
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 8
- 108091026890 Coding region Proteins 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 208000035475 disorder Diseases 0.000 description 7
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 6
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 6
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 5
- CJLHTKGWEUGORV-UHFFFAOYSA-N Artemin Chemical compound C1CC2(C)C(O)CCC(=C)C2(O)C2C1C(C)C(=O)O2 CJLHTKGWEUGORV-UHFFFAOYSA-N 0.000 description 4
- 102100024506 Bone morphogenetic protein 2 Human genes 0.000 description 4
- 102100024505 Bone morphogenetic protein 4 Human genes 0.000 description 4
- 102000003951 Erythropoietin Human genes 0.000 description 4
- 102100031939 Erythropoietin Human genes 0.000 description 4
- 108090000394 Erythropoietin Proteins 0.000 description 4
- 102100040898 Growth/differentiation factor 11 Human genes 0.000 description 4
- 102100035368 Growth/differentiation factor 6 Human genes 0.000 description 4
- 101000762366 Homo sapiens Bone morphogenetic protein 2 Proteins 0.000 description 4
- 101000762379 Homo sapiens Bone morphogenetic protein 4 Proteins 0.000 description 4
- 101000893545 Homo sapiens Growth/differentiation factor 11 Proteins 0.000 description 4
- 101001023964 Homo sapiens Growth/differentiation factor 6 Proteins 0.000 description 4
- 208000007502 anemia Diseases 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- 229940105423 erythropoietin Drugs 0.000 description 4
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 4
- 102000034615 Glial cell line-derived neurotrophic factor Human genes 0.000 description 3
- 108091010837 Glial cell line-derived neurotrophic factor Proteins 0.000 description 3
- 102100040896 Growth/differentiation factor 15 Human genes 0.000 description 3
- 101000893549 Homo sapiens Growth/differentiation factor 15 Proteins 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 102100034135 Activin receptor type-1C Human genes 0.000 description 2
- 102100026376 Artemin Human genes 0.000 description 2
- 101710205806 Artemin Proteins 0.000 description 2
- 102100028726 Bone morphogenetic protein 10 Human genes 0.000 description 2
- 102100028727 Bone morphogenetic protein 15 Human genes 0.000 description 2
- 102100024504 Bone morphogenetic protein 3 Human genes 0.000 description 2
- 102100022526 Bone morphogenetic protein 5 Human genes 0.000 description 2
- 102100022525 Bone morphogenetic protein 6 Human genes 0.000 description 2
- 102100022544 Bone morphogenetic protein 7 Human genes 0.000 description 2
- 102100040892 Growth/differentiation factor 2 Human genes 0.000 description 2
- 102100035364 Growth/differentiation factor 3 Human genes 0.000 description 2
- 102100035379 Growth/differentiation factor 5 Human genes 0.000 description 2
- 102100035363 Growth/differentiation factor 7 Human genes 0.000 description 2
- 102100039939 Growth/differentiation factor 8 Human genes 0.000 description 2
- 101000799193 Homo sapiens Activin receptor type-1C Proteins 0.000 description 2
- 101000695367 Homo sapiens Bone morphogenetic protein 10 Proteins 0.000 description 2
- 101000695360 Homo sapiens Bone morphogenetic protein 15 Proteins 0.000 description 2
- 101000762375 Homo sapiens Bone morphogenetic protein 3 Proteins 0.000 description 2
- 101000899388 Homo sapiens Bone morphogenetic protein 5 Proteins 0.000 description 2
- 101000899390 Homo sapiens Bone morphogenetic protein 6 Proteins 0.000 description 2
- 101000899361 Homo sapiens Bone morphogenetic protein 7 Proteins 0.000 description 2
- 101000893585 Homo sapiens Growth/differentiation factor 2 Proteins 0.000 description 2
- 101001023986 Homo sapiens Growth/differentiation factor 3 Proteins 0.000 description 2
- 101001023988 Homo sapiens Growth/differentiation factor 5 Proteins 0.000 description 2
- 101001023968 Homo sapiens Growth/differentiation factor 7 Proteins 0.000 description 2
- 101000886562 Homo sapiens Growth/differentiation factor 8 Proteins 0.000 description 2
- 101000692878 Homo sapiens Regulator of MON1-CCZ1 complex Proteins 0.000 description 2
- 102100021584 Neurturin Human genes 0.000 description 2
- 108010015406 Neurturin Proteins 0.000 description 2
- 208000002903 Thalassemia Diseases 0.000 description 2
- 102000046299 Transforming Growth Factor beta1 Human genes 0.000 description 2
- 102000011117 Transforming Growth Factor beta2 Human genes 0.000 description 2
- 101800002279 Transforming growth factor beta-1 Proteins 0.000 description 2
- 101800000304 Transforming growth factor beta-2 Proteins 0.000 description 2
- 102000056172 Transforming growth factor beta-3 Human genes 0.000 description 2
- 108090000097 Transforming growth factor beta-3 Proteins 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 108010023082 activin A Proteins 0.000 description 2
- 108010023079 activin B Proteins 0.000 description 2
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 2
- 239000000833 heterodimer Substances 0.000 description 2
- 206010028537 myelofibrosis Diseases 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- -1 persefin Proteins 0.000 description 2
- 239000000018 receptor agonist Substances 0.000 description 2
- 229940044601 receptor agonist Drugs 0.000 description 2
- 208000007056 sickle cell anemia Diseases 0.000 description 2
- 102100034111 Activin receptor type-1 Human genes 0.000 description 1
- 102100034134 Activin receptor type-1B Human genes 0.000 description 1
- 102100027052 Bone morphogenetic protein receptor type-1B Human genes 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 101000799140 Homo sapiens Activin receptor type-1 Proteins 0.000 description 1
- 101000799189 Homo sapiens Activin receptor type-1B Proteins 0.000 description 1
- 101000984546 Homo sapiens Bone morphogenetic protein receptor type-1B Proteins 0.000 description 1
- 101100490437 Mus musculus Acvrl1 gene Proteins 0.000 description 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 1
- 108010025020 Nerve Growth Factor Proteins 0.000 description 1
- 102000007072 Nerve Growth Factors Human genes 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000000423 cell based assay Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 125000003473 lipid group Chemical group 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 239000003900 neurotrophic factor Substances 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022102709A JP7504947B2 (ja) | 2016-10-05 | 2022-06-27 | Ｔｇｆ－ベータスーパーファミリーｉ型およびｉｉ型受容体ヘテロ多量体ならびにその使用 |
| JP2024095366A JP2024113195A (ja) | 2016-10-05 | 2024-06-12 | Ｔｇｆ－ベータスーパーファミリーｉ型およびｉｉ型受容体ヘテロ多量体ならびにその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662404563P | 2016-10-05 | 2016-10-05 | |
| US62/404,563 | 2016-10-05 | ||
| PCT/US2017/055420 WO2018067873A2 (en) | 2016-10-05 | 2017-10-05 | Tgf-beta superfamily type i and type ii receptor heteromultimers and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022102709A Division JP7504947B2 (ja) | 2016-10-05 | 2022-06-27 | Ｔｇｆ－ベータスーパーファミリーｉ型およびｉｉ型受容体ヘテロ多量体ならびにその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019536439A JP2019536439A (ja) | 2019-12-19 |
| JP2019536439A5 true JP2019536439A5 (enExample) | 2020-11-12 |
| JP7097354B2 JP7097354B2 (ja) | 2022-07-07 |
Family
ID=61831499
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019518301A Active JP7097354B2 (ja) | 2016-10-05 | 2017-10-05 | Ｔｇｆ－ベータスーパーファミリーｉ型およびｉｉ型受容体ヘテロ多量体ならびにその使用 |
| JP2022102709A Active JP7504947B2 (ja) | 2016-10-05 | 2022-06-27 | Ｔｇｆ－ベータスーパーファミリーｉ型およびｉｉ型受容体ヘテロ多量体ならびにその使用 |
| JP2024095366A Pending JP2024113195A (ja) | 2016-10-05 | 2024-06-12 | Ｔｇｆ－ベータスーパーファミリーｉ型およびｉｉ型受容体ヘテロ多量体ならびにその使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022102709A Active JP7504947B2 (ja) | 2016-10-05 | 2022-06-27 | Ｔｇｆ－ベータスーパーファミリーｉ型およびｉｉ型受容体ヘテロ多量体ならびにその使用 |
| JP2024095366A Pending JP2024113195A (ja) | 2016-10-05 | 2024-06-12 | Ｔｇｆ－ベータスーパーファミリーｉ型およびｉｉ型受容体ヘテロ多量体ならびにその使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US11440949B2 (enExample) |
| EP (1) | EP3522912A4 (enExample) |
| JP (3) | JP7097354B2 (enExample) |
| AU (2) | AU2017338915B2 (enExample) |
| CA (1) | CA3039545A1 (enExample) |
| WO (1) | WO2018067873A2 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20170306027A1 (en) | 2016-04-06 | 2017-10-26 | Acceleron Pharma Inc. | Alk7 antagonists and uses thereof |
| AU2017338916B2 (en) | 2016-10-05 | 2022-03-24 | Acceleron Pharma Inc. | Variant ActRIIB proteins and uses thereof |
| EP3788067A4 (en) | 2018-05-03 | 2022-01-19 | Acceleron Pharma Inc. | NOVEL BINDERS OF TGFBETA SUPERFAMILY LIGANDS AND THEIR USES |
| AU2019262139A1 (en) * | 2018-05-03 | 2020-11-26 | Acceleron Pharma Inc. | Multispecific binders of TGFβ-superfamily ligands and uses thereof |
| WO2020198293A1 (en) * | 2019-03-25 | 2020-10-01 | Northshore University Health System | Methods and compositions comprising enhanced targeted immune gene therapy for the treatment of cancer |
| WO2021158695A1 (en) * | 2020-02-03 | 2021-08-12 | Acceleron Pharma Inc. | Compositions and methods for treating pulmonary hypertension |
| US20230183319A1 (en) * | 2020-02-03 | 2023-06-15 | Acceleron Pharma Inc. | Variant actriib proteins and uses thereof |
| US12508262B2 (en) | 2020-04-30 | 2025-12-30 | Keros Therapeutics, Inc. | Methods of using ALK2 inhibitors |
| WO2022098812A1 (en) | 2020-11-04 | 2022-05-12 | Keros Therapeutics, Inc. | Methods of treating iron overload |
| US20250002588A1 (en) | 2023-04-07 | 2025-01-02 | Diagonal Therapeutics Inc. | Bispecific agonistic antibodies to activin a receptor like type 1 (alk1) |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002510198A (ja) | 1997-05-16 | 2002-04-02 | ザ プロクター アンド ギャンブル カンパニー | スクリーニングのための骨形態形成タンパク質（ｂｍｐ）受容体複合体の使用 |
| US7521211B2 (en) * | 2005-04-05 | 2009-04-21 | Regeneron Pharmaceuticals, Inc | IGF-1 and IGF-2 chimeric polypeptides and therapeutic uses thereof |
| WO2010031168A1 (en) | 2008-09-17 | 2010-03-25 | National Research Council Of Canada | HETERO-MULTIVALENT BINDING AGENTS FOR MEMBERS OF THE TGFβ SUPERFAMILY |
| KR20110047255A (ko) * | 2008-09-26 | 2011-05-06 | 로슈 글리카트 아게 | 이중특이적 항-ｅｇｆｒ／항-ｉｇｆ-１ｒ 항체 |
| CN103429620B (zh) * | 2010-11-05 | 2018-03-06 | 酵活有限公司 | 在Fc结构域中具有突变的稳定异源二聚的抗体设计 |
| US10851178B2 (en) | 2011-10-10 | 2020-12-01 | Xencor, Inc. | Heterodimeric human IgG1 polypeptides with isoelectric point modifications |
| RU2678117C2 (ru) | 2012-11-02 | 2019-01-23 | Селджин Корпорейшн | Антагонисты активина-actrii и их применение для лечения нарушений костной ткани и других нарушений |
| CN114699529A (zh) * | 2014-06-13 | 2022-07-05 | 阿塞勒隆制药公司 | 用于治疗溃疡的方法和组合物 |
| CA2980757A1 (en) | 2015-03-26 | 2016-09-29 | Acceleron Pharma Inc. | Follistatin-related fusion proteins and uses thereof |
| JP7082484B2 (ja) | 2015-04-01 | 2022-06-08 | 中外製薬株式会社 | ポリペプチド異種多量体の製造方法 |
| EP3280435B1 (en) | 2015-04-06 | 2021-06-02 | Acceleron Pharma Inc. | Tgf-beta superfamily type i and type ii receptor heteromultimers and uses thereof |
| MA41919A (fr) | 2015-04-06 | 2018-02-13 | Acceleron Pharma Inc | Hétéromultimères alk4:actriib et leurs utilisations |
| CN113683708A (zh) | 2015-04-06 | 2021-11-23 | 阿塞勒隆制药公司 | 单臂i型和ii型受体融合蛋白和其用途 |
| US20170306027A1 (en) | 2016-04-06 | 2017-10-26 | Acceleron Pharma Inc. | Alk7 antagonists and uses thereof |
| CN110678195A (zh) | 2016-10-05 | 2020-01-10 | 阿塞勒隆制药公司 | ALK4:ActRIIB异多聚体及其用途 |
-
2017
- 2017-10-05 EP EP17859218.4A patent/EP3522912A4/en active Pending
- 2017-10-05 US US16/340,040 patent/US11440949B2/en active Active
- 2017-10-05 AU AU2017338915A patent/AU2017338915B2/en active Active
- 2017-10-05 JP JP2019518301A patent/JP7097354B2/ja active Active
- 2017-10-05 WO PCT/US2017/055420 patent/WO2018067873A2/en not_active Ceased
- 2017-10-05 CA CA3039545A patent/CA3039545A1/en active Pending
-
2022
- 2022-06-27 JP JP2022102709A patent/JP7504947B2/ja active Active
- 2022-09-12 US US17/942,695 patent/US12421295B2/en active Active
-
2024
- 2024-06-12 JP JP2024095366A patent/JP2024113195A/ja active Pending
-
2025
- 2025-02-12 AU AU2025200960A patent/AU2025200960A1/en active Pending
- 2025-08-11 US US19/296,454 patent/US20250368720A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7617962B2 (ja) | バリアントＡｃｔＲＩＩＢタンパク質およびその使用 | |
| JP7320571B2 (ja) | 筋消耗疾患治療用の新規なハイブリッドａｃｔｒｉｉｂリガンド捕集タンパク質 | |
| EP3889171B1 (en) | Tgf-beta superfamily type i and type ii receptor heteromultimers and uses thereof | |
| JP6810702B2 (ja) | シングルアームｉ型およびｉｉ型受容体融合タンパク質およびその使用 | |
| EP3202459B1 (en) | Actriib antagonists and dosing and uses thereof for treating obesity or type 2 diabetes by regulating body fat content | |
| JP7504947B2 (ja) | Ｔｇｆ－ベータスーパーファミリーｉ型およびｉｉ型受容体ヘテロ多量体ならびにその使用 | |
| DK2332977T3 (en) | ActRII receptor polypeptides | |
| CN110198743B (zh) | 用于治疗肾脏疾病的组合物和方法 | |
| CA2723449C (en) | Methods and compositions based on alk1 antagonists for modulating angiogenesis and pericyte coverage | |
| JP2019536440A5 (enExample) | ||
| ES3011833T3 (en) | Engineered tgf-beta monomers and their use for inhibiting tgf-beta signaling | |
| CN113227134A (zh) | 抗体的Fc区变体 | |
| JP2014506452A5 (enExample) | ||
| JP2003519481A5 (enExample) | ||
| US20140227254A1 (en) | Antagonists of bmp9, bmp10, alk1 and other alk1 ligands, and uses thereof | |
| JP2019527547A5 (enExample) | ||
| JP2020500511A5 (enExample) | ||
| AU678380B2 (en) | Morphogenic protein soluble complex and composition thereof | |
| CA3000697A1 (en) | Treatment of bile acid disorders | |
| CA3099325A1 (en) | Novel binders of tgf.beta.-superfamily ligands and uses thereof | |
| Xu et al. | LRIG1 extracellular domain: structure and function analysis | |
| JP6185926B2 (ja) | 軟骨形成を誘導するためのｇｄｆ−５変異体 | |
| CN115702169A (zh) | 包含促红细胞生成素多肽的融合蛋白 | |
| EP4474394A1 (en) | Usag-1 molecule-targeting neutralizing antibody for tooth regeneration treatment | |
| HK40114319A (en) | Usag-1 molecule-targeting neutralizing antibody for tooth regeneration treatment |